2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
NCT01173211 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 183
Last updated 2014-12-24
Summary
The purpose of this study is to see how much antibody (proteins produced by the immune system that help fight infections) the body makes after getting a flu vaccine. Researchers will also look at how the body reacts to the flu vaccine and how it affects the babies of pregnant women. The study will enroll approximately 240 women ages 18-39 years, including 180 pregnant women in their second or third trimester of pregnancy (at least 14 weeks pregnant) and 60 non-pregnant women. Participants will be randomly (by chance) assigned to 1 of 3 vaccine groups. Each participant will receive one shot of a 2010-2011 flu season licensed vaccine. The vaccine will be given as an intramuscular injection (shot in the muscle) in the upper arm. Study procedures include pregnancy testing, blood draws, and memory aids. Patient participation may be up to 8 months. The information from this study will help guide researchers in developing flu vaccines for pregnant women.
Conditions
Interventions
- BIOLOGICAL
-
Trivalent inactivated influenza vaccine
Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
- BIOLOGICAL
-
Trivalent inactivated influenza vaccine
Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber..
- BIOLOGICAL
-
Trivalent inactivated influenza vaccine
Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone®, Agriflu® and Fluarix® do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 39 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-09-30
- Primary Completion
- 2011-11-30
- Completion
- 2011-11-30
Countries
- United States
Study Locations
More Related Trials
-
Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
NCT00845429 ·Status: COMPLETED ·Phase: PHASE2
-
Sanofi Pasteur, TIV + H1N1, Pediatric Population
NCT00943202 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Flu Vaccine Doses in Children
NCT01164553 ·Status: COMPLETED ·Phase: PHASE1
-
Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry
NCT02148211 ·Status: COMPLETED
-
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women
NCT07211152 ·Status: RECRUITING ·Phase: PHASE3
-
H1N1 Vaccine in Pregnant Women
NCT00963430 ·Status: COMPLETED ·Phase: PHASE2
-
Novartis H1N1 Vaccine in Pregnant Women
NCT00992719 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women
NCT01024400 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of RIV4 Versus IIV4 in Pregnant Women
NCT03969641 ·Status: COMPLETED ·Phase: PHASE4
-
Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women
NCT01181323 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age
NCT01258595 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine
NCT00677820 ·Status: COMPLETED ·Phase: PHASE4
-
Sanofi H1N1 + TIV - Adults and Elderly
NCT00943878 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of H1N1 Influenza Vaccination in Pregnant Women
NCT01842997 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults
NCT00328107 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects
NCT01356316 ·Status: COMPLETED ·Phase: PHASE4
-
Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone
NCT01498718 ·Status: COMPLETED ·Phase: PHASE1
-
Maternal Flu Vaccine Trial in Bamako, Mali
NCT01430689 ·Status: COMPLETED ·Phase: PHASE4
-
Brief Influenza Vaccine Education to Pregnant Women
NCT01772901 ·Status: COMPLETED ·Phase: NA
-
Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects
NCT02256488 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
NCT01857206 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
NCT02212106 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants
NCT01218685 ·Status: COMPLETED
-
A Study of Influenza Virus Vaccines in Children and Adults
NCT00988143 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
NCT01712984 ·Status: COMPLETED ·Phase: PHASE3